SCHEMBL5501154

SCHEMBL5501154

Cc1cccc(C)c1-c1ccc2nc(Nc3ccc(OCCCN4CCCCC4)cc3)ncc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 15/20 0.69
BRAF P15056 2/20 0.65
PDGFRB P09619 5/20 0.59
KDR P35968 4/20 0.59
LCK P06239 3/20 0.59
YES1 P07947 3/20 0.59
FGFR1 P11362 2/20 0.59
EGFR P00533 2/20 0.59
TEK Q02763 2/20 0.59
ABL1 P00519 2/20 0.59
LYN P07948 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2D6 P10635 2/20 0.59
CYP2C19 P33261 2/20 0.59
EPHB4 P54760 2/20 0.59
RAF1 P04049 1/20 0.59
FYN P06241 1/20 0.59
RPS6KB1 P23443 1/20 0.59
CSK P41240 1/20 0.59
BLK P51451 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230249 0.95 SRC (0.77) SRCBRAFPDGFRBKDRLCK
SCHEMBL5494768 0.83 BRAF (0.57) SRCBRAFPDGFRBKDRLCK
SCHEMBL5490360 0.82 BRAF (0.64) SRCBRAFKDRLCKFGFR1
SCHEMBL4276831 0.82 SRC (1.00) SRCPDGFRBKDRLCKYES1
SCHEMBL15683174 0.80 SRC (0.77) SRCPDGFRBKDRLCKYES1
SCHEMBL2582023 0.80 SRC (0.53) SRCBRAFPDGFRBKDRLCK
SCHEMBL226164 0.80 SRC (0.55) SRCBRAFPDGFRBKDRLCK
SCHEMBL226165 0.80 SRC (0.55) SRCBRAFPDGFRBKDRLCK
SCHEMBL231133 0.79 SRC (0.51) SRCBRAFPDGFRBKDRLCK
SCHEMBL4265763 0.79 SRC (1.00) SRCPDGFRBKDRLCKYES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 SRC 248/4885BRAF 100/4885PDGFRB 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.